meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 2nd line (L2)
1
myofibroblastic tumors
neurofibroma
neutropenia
osteosarcoma
ovarian cancer (OC)
9
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
avelumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
olaparib
rucaparib
target therapy
multikinase inhibitor
nintedanib
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab plus SoC
title
placebo plus SoC
title
IMagyn-050 (all population), 2021 NCT03038100 mOC - L1 - all population 651/650
IMagyn-050 (PDL1 >1%), 2021 NCT03038100 mOC - L1 - PDL1 positive 391/393
Pathology:
mOC - L1 - all population;
mOC - L1 - PDL1 positive;
mOC - L1 - all population
mOC - L1 - PDL1 positive
IMagyn-050 (all population), 2021
IMagyn-050 (PDL1 >1%), 2021
atezolizumab plus SoC
2
T1
T1
placebo plus SoC
0
T0
T0